Revelation Biosciences Inc.
Organization details
- Legal name
- Revelation Biosciences Inc.
- Former names
- Petra Acquisition Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- REVB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001810560
- EIN
- 84-3898466
Board of directors
-
Curt H. LaBelle · DirectorSince 2023
-
George F. Tidmarsh · DirectorSince 2023
-
James Rolke · Director · Chief Executive OfficerSince 2023
-
Jennifer Carver · DirectorSince 2023
-
Jess Roper · DirectorSince 2023
-
Lakhmir S. Chawla · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 23, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Jennifer Carver Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Lakhmir S. Chawla Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Jess Roper Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Grant or award | +208,073 | — | — |
| Aug 17, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Grant or award | +208,076 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Gift | −208,073 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Gift | +208,073 | — | — |
| Apr 30, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Shares withheld for tax | −10,115 | $1.13 | $11,430 |
| Apr 30, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Shares withheld for tax | −13,285 | $1.10 | $14,614 |
| Feb 4, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Shares withheld for tax | −13,100 | $1.65 | $21,615 |
| Feb 3, 2026 | Jess Roper Director | Shares withheld for tax | −1,591 | $1.85 | $2,943 |
| Feb 3, 2026 | Lakhmir S. Chawla Director | Shares withheld for tax | −2,261 | $1.85 | $4,183 |
| Feb 3, 2026 | Jennifer Carver Director | Shares withheld for tax | −1,661 | $1.87 | $3,106 |
| Feb 3, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Shares withheld for tax | −8,521 | $1.86 | $15,849 |
| Jan 8, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Grant or award | +532,829 | $0.90 | $479,546 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Revelation Biosciences Inc.
Who is the CEO of Revelation Biosciences Inc.?
James Rolke is Revelation Biosciences Inc.'s Chief Executive Officer.
How many directors are on Revelation Biosciences Inc.'s board?
Revelation Biosciences Inc.'s board has 6 directors: Curt H. LaBelle, George F. Tidmarsh, James Rolke, Jennifer Carver, Jess Roper and Lakhmir S. Chawla.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="revelation-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.